This study retrospectively reviewed the medical records of patients with advanced non‐small cell lung cancer (NSCLC) who had received PD‐1/PD‐L1 inhibitor monotherapy between March 2016 and February 2018. This evidence concerns the gene PDCD1 and lung cancer.